Literature DB >> 29604506

Association between serum uric acid level and multiple system atrophy: A meta-analysis.

Xi Zhang1, De-Shan Liu2, Chun-Yao An3, Yu-Zhao Liu4, Xiao-Hong Liu3, Fang Zhang3, Lu-Ning Ning3, Chang-Ling Li5, Chun-Mei Ma5, Rui-Ting Hu5.   

Abstract

OBJECTIVES: Lower serum uric acid (UA) levels are considered to be related to the risk to develop many neurodegenerative disorders. However, the association between serum UA level and multiple system atrophy (MSA) remains controversial. The aim of this meta-analysis was to evaluate the relationship between serum UA level and MSA. PATIENTS AND METHODS: PubMed, Web of Science, Embase, Cochrane Library and China National Knowledge Infrastructure (CNKI) were searched for eligible studies. Standardized mean difference (SMD) and 95% confidence intervals (95% CI) were calculated in a fixed-effects model or a random-effects model when appropriate. Subgroup analyses were carried out based on gender. A total of 6 eligible studies involving 547 MSA patients and 637 healthy individuals were identified.
RESULTS: Meta-analysis results revealed that individuals with MSA had lower sera levels of UA as compared with healthy controls (pooled SMD is -0.51, 95%CI: -0.88 to -0.14; p = 0.006). The subgroup analysis to detect sex differences showed that the pooled SMD was -0.61 (95% CI: -0.82 to -0.40; p < 0.0001) for males and -0.22 (95% CI: -0.55 to 0.10; p = 0.18) for females compared with healthy controls.
CONCLUSION: Our meta-analysis revealed that lower serum level of UA is associated with an increased risk of MSA and the relationship is significant in men but not in women.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gender; Meta-analysis; Multiple system atrophy; Uric acid

Mesh:

Substances:

Year:  2018        PMID: 29604506     DOI: 10.1016/j.clineuro.2018.03.023

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  4 in total

Review 1.  Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy.

Authors:  Lisa Mészáros; Alana Hoffmann; Jeanette Wihan; Jürgen Winkler
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

2.  Time to reconsider urate: Neuroprotective potential may prevail on cardiovascular risk in animal models and clinical trials.

Authors:  Martina Petruzzo; Marcello Moccia
Journal:  EBioMedicine       Date:  2018-11-19       Impact factor: 8.143

3.  Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 disease.

Authors:  Shin-Ichi Ueno; Taku Hatano; Ayami Okuzumi; Shinji Saiki; Yutaka Oji; Akio Mori; Takahiro Koinuma; Motoki Fujimaki; Haruka Takeshige-Amano; Akihide Kondo; Naoyuki Yoshikawa; Takahiro Nojiri; Makoto Kurano; Keiko Yasukawa; Yutaka Yatomi; Hitoshi Ikeda; Nobutaka Hattori
Journal:  Ann Clin Transl Neurol       Date:  2020-02-14       Impact factor: 4.511

4.  Urate is closely linked to white matter integrity in multiple system atrophy.

Authors:  Han Soo Yoo; Seok Jong Chung; Yang Hyun Lee; Byoung Seok Ye; Young H Sohn; Hunki Kwon; Phil Hyu Lee
Journal:  Ann Clin Transl Neurol       Date:  2020-06       Impact factor: 4.511

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.